当前期刊: The Lancet Infectious Diseases Go to current issue    加入关注   
显示样式:        排序: 导出
我的关注
我的收藏
您暂时未登录!
登录
  • Safety and immunogenicity of vesicular stomatitis virus-based vaccines for Ebola virus disease
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-14
    Marc-Antoine de La Vega; Gary P Kobinger
    更新日期:2020-01-15
  • The Stockholm paradigm
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-14
    Joanne Cable
    更新日期:2020-01-15
  • Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-14
    David K Clarke; Rong Xu; Demetrius Matassov; Theresa E Latham; Ayuko Ota-Setlik; Cheryl S Gerardi; Amara Luckay; Susan E Witko; Luz Hermida; Terry Higgins; Marc Tremblay; Susan Sciotto-Brown; Tracy Chen; Michael A Egan; Janice M Rusnak; Lucy A Ward; John H Eldridge
    更新日期:2020-01-15
  • Fighting malaria with ivermectin: a novel malaria control tool
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-13
    Miranda I Teboh-Ewungkem; Gideon A Ngwa
    更新日期:2020-01-14
  • Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-13
    Hannah C Slater; Brian D Foy; Kevin Kobylinski; Carlos Chaccour; Oliver J Watson; Joel Hellewell; Ghaith Aljayyoussi; Teun Bousema; Jeremy Burrows; Umberto D'Alessandro; Haoues Alout; Feiko O Ter Kuile; Patrick G T Walker; Azra C Ghani; Menno R Smit
    更新日期:2020-01-14
  • Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-07
    Fiona V Cresswell; Lillian Tugume; Nathan C Bahr; Richard Kwizera; Ananta S Bangdiwala; Abdu K Musubire; Morris Rutakingirwa; Enock Kagimu; Edwin Nuwagira; Edward Mpoza; Joshua Rhein; Darlisha A Williams; Conrad Muzoora; Daniel Grint; Alison M Elliott; David B Meya; David R Boulware
    更新日期:2020-01-08
  • Zoonotic spillover infections with Borna disease virus 1 leading to fatal human encephalitis, 1999–2019: an epidemiological investigation
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-07
    Hans Helmut Niller; Klemens Angstwurm; Dennis Rubbenstroth; Kore Schlottau; Arnt Ebinger; Sebastian Giese; Silke Wunderlich; Bernhard Banas; Leonie F Forth; Donata Hoffmann; Dirk Höper; Martin Schwemmle; Dennis Tappe; Jonas Schmidt-Chanasit; Daniel Nobach; Christiane Herden; Christoph Brochhausen; Natalia Velez-Char; Andreas Mamilos; Kirsten Utpatel; Matthias Evert; Saida Zoubaa; Markus J Riemenschneider; Viktoria Ruf; Jochen Herms; Georg Rieder; Mario Errath; Kaspar Matiasek; Jürgen Schlegel; Friederike Liesche-Starnecker; Bernhard Neumann; Kornelius Fuchs; Ralf A Linker; Bernd Salzberger; Tobias Freilinger; Lisa Gartner; Jürgen J Wenzel; Udo Reischl; Wolfgang Jilg; André Gessner; Jonathan Jantsch; Martin Beer; Barbara Schmidt
    更新日期:2020-01-08
  • 更新日期:2020-01-08
  • Diagnostic tests for tuberculous meningitis
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-07
    Angharad G Davis; Robert J Wilkinson

    Tuberculous meningitis is the most serious manifestation of tuberculosis, with mortality in approximately 50% of HIV co-infected people. A major factor contributing to the poor outcome of tuberculous meningitis is delayed diagnosis due to a lack of rapid, accurate diagnostic tests. Until recently, these tests were restricted to smear microscopy of cerebrospinal fluid (CSF) and microbiological culture. The former tends operationally to be of low sensitivity and the latter often renders a result too late to be clinically meaningful. The diagnosis of drug-resistant disease presents further difficulties.

    更新日期:2020-01-08
  • Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-07
    Joseph Donovan; Do Dang Anh Thu; Nguyen Hoan Phu; Vu Thi Mong Dung; Tran Phu Quang; Ho Dang Trung Nghia; Pham Kieu Nguyet Oanh; Tran Bao Nhu; Nguyen Van Vinh Chau; Vu Thi Ngoc Ha; Vu Thi Ty Hang; Dong Huu Khanh Trinh; Ronald B Geskus; Le Van Tan; Nguyen Thuy Thuong Thuong; Guy E Thwaites
    更新日期:2020-01-08
  • New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-12-23
    Andreas K Lindner; Veerle Lejon; François Chappuis; Jorge Seixas; Leon Kazumba; Michael P Barrett; Erick Mwamba; Olema Erphas; Elie A Akl; Gemma Villanueva; Hanna Bergman; Pere Simarro; Augustin Kadima Ebeja; Gerardo Priotto; Jose Ramon Franco
    更新日期:2019-12-25
  • Correction to Lancet Infect Dis 2019; 19: 143–55
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-12-23

    Hemelaar J, Elangovan R, Yun J, et al; WHO–UNAIDS Network for HIV Isolation Characterisation. Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis 2019; 19: 143–55—In figure 3 of this Article, one segment of the pie charts for east Africa and central Africa was mislabelled as CRF02_AG (yellow) instead of D (pink). This change does not affect the written interpretation. This correction has been made to the online version as of Dec 23, 2019.

    更新日期:2019-12-25
  • Dare we dream of the end of malaria?
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    The Lancet Infectious Diseases
    更新日期:2019-12-25
  • Cover artist for 2020
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Marco De Ambrogi
    更新日期:2019-12-25
  • Early childhood diarrhoea: from data to interventions
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-30
    Karen H Keddy

    The Global Burden of Diseases (GBD) project was originally commissioned by the World Bank in 1990, with the intent to define disease burdens and optimise interventions depending on local resources. The excessive uncertainty of results regarding certain countries due to absent or poor data was problematic and meant that those countries that would most benefit from the information could be disadvantaged by inappropriate interventions based on questionable data. 30 years after the project was initiated, the GBD 2017 Diarrhoeal Disease Collaborators have produced an Article that answers, in part, the question regarding optimal interventions. Analysing the data at a country level, the authors have defined a hierarchy of interventions that have decreased diarrhoea burdens and mortality in the vulnerable population of children younger than 5 years.

    更新日期:2019-12-25
  • Trends in the global burden of paediatric lower respiratory infections
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-30
    Carina King; Eric D McCollum

    As the leading cause of infectious deaths in children, reducing lower respiratory infections (LRIs) will be the key to achieving Sustainable Development Goal 3.2. However, of the biggest infectious killers, LRI remains the condition with the least funding on a global level. In The Lancet Infectious Diseases, the GBD 2017 Lower Respiratory Infections Collaborators present modelled trends in LRI incident cases and mortality and estimate the role of 13 modifiable protective and preventive risk factors in these spatiotemporal changes using the Global Burden of Disease (GBD) dataset.

    更新日期:2019-12-25
  • Turning influenza vaccinology on its head to reveal the stalk
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-17
    Sophie A Valkenburg; Benjamin J Cowling

    Inactivated influenza virus vaccines (IIVs) have been in use for more than 70 years with no major changes in the underlying technology. Limitations of these vaccines include the long production cycle, which requires strain selection well in advance of their use; provision of only moderate protection when vaccine strains match circulating strains; protection that wanes quickly; potential issues with repeated annual immunisation, such as reduced haemagglutination-inhibition boosting and protection from infection; and no protection against novel outbreak or pandemic strains. IIVs primarily work by stimulating antibodies against the head domain of the haemagglutinin protein, but these antibodies are undermined by rapid antigenic drift in circulating strains. Therefore, improvements in influenza vaccine design are urgently needed.

    更新日期:2019-12-25
  • 更新日期:2019-12-25
  • 更新日期:2019-12-25
  • What makes a score a winner?
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-30
    Jonathon R Campbell; Dick Menzies
    更新日期:2019-12-25
  • Tuberculosis: an instrument of early mortality in life course
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-29
    Barbara Reis-Santos; Marli Souza Rocha
    更新日期:2019-12-25
  • HTLV-1: the silent impact revealed
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-21
    Lucy B M Cook; Graham P Taylor

    The 1983 recovery of a human retrovirus from a patient at risk of acquired immunodeficiency syndrome is regarded as one of the major medical discoveries of the 20th century. Many will recall the original name for HIV in North America was human T-cell lymphotropic virus (HTLV) type III, raising the question of what happened to HTLV types I and II.

    更新日期:2019-12-25
  • Is there a silver lining to the Zika virus epidemic in the Americas?
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Sylvia Becker-Dreps; Elizabeth M Stringer; Filemon Bucardo; Natalie M Bowman; Michael J Boivin

    It is hard to find anything positive to say about an epidemic of an emerging virus that infects pregnant women, targets developing fetuses' neural progenitor cells, and disrupts the sequence of neural development to cause a devastating syndrome resulting in lifelong disabilities. Infants with microcephaly became the faces of the Zika virus epidemic in the Americas, which affected almost all countries in the western hemisphere in 2014–17. By the end of 2017, Zika virus has nearly disappeared from the Americas as quickly as it emerged. Now that the dust is settling, what have the scientific and public health communities learned? Is there a silver lining to Zika's devastation?

    更新日期:2019-12-25
  • Viral emergence and immune interplay in flavivirus vaccines
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Carlo Fischer; Edmilson F de Oliveira-Filho; Jan Felix Drexler
    更新日期:2019-12-25
  • Preparedness for emerging epidemic threats: a Lancet Infectious Diseases Commission
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Vernon J Lee; Ximena Aguilera; David Heymann; Annelies Wilder-Smith; Vernon J. Lee; Ximena Aguilera; David L. Heymann; Annelies Wilder-Smith; Daniel G. Bausch; Sylvie Briand; Christianne Bruschke; Eduardo H. Carmo; Sean Cleghorn; Lalit Dandona; Christl Donnelly; Ibrahima Socé Fall; Jane Halton; Richard Hatchett; Felicia Hong; Peter Horby; Chikwe Ihekweazu; Michael Jacobs; Kamran Khan; Yijun Lin; Gabriel Leung; Constance Low; Bethan F. McDonald; Ziad A. Memish; Ryan Morhard; Deborah HL Ng; John Nkengasong; Junxiong Pang; Stephen C. Redd; Karen Tan; Wen Qing Yeo

    At any time, an emerging, lethal, and highly transmissible pathogen might pose a risk of being spread globally because of the interconnectedness of the global population. ,  Emerging epidemic threats are occurring with increasing scale, duration, and effect, often disrupting travel and trade, and damaging both national and regional economies. ,  Even geographically limited outbreaks such as the Ebola virus disease in Africa might have a global effect.

    更新日期:2019-12-25
  • Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Hung-Jen Tang; Chih-Cheng Lai

    We read with interest the Article by Marin Kollef and colleagues reporting the findings of the ASPECT-NP trial. High-dose ceftolozane–tazobactam was reported to be non-inferior to meropenem in the treatment of nosocomial pneumonia, including ventilator-associated pneumonia.

    更新日期:2019-12-25
  • Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia – Authors' reply
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Marin H Kollef; Álvaro Réa-Neto; Richard G Wunderink; Christopher J Bruno; Elizabeth G Rhee

    We thank Hung-Jen Tang and Chih-Cheng Lai for their interest in our Article. Contemporary non-inferiority clinical trials of hospital-acquired pneumonia and ventilator-associated pneumonia assess two main efficacy endpoints: 28 day all-cause mortality and clinical response after the end of therapy. Although regulatory agencies differ in their preferred primary endpoint, it is crucial that results for all-cause mortality and clinical response are supportive of each other when evaluating new therapies for hospital-acquired and ventilator-associated pneumonia.

    更新日期:2019-12-25
  • Preventing paralytic polio caused by vaccine-derived poliovirus type 2
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Carlos Franco-Paredes; Jose I Santos-Preciado; Andres F Henao-Martinez; Alfonso J Rodriguez-Morales; Peter Carrasco

    Grace Macklin and colleagues reported the results of a systematic review on the effect of polio vaccine schedules on induction of humoral and intestinal immunity and concluded that the addition of one dose of inactivated poliovirus vaccine (IPV) for all birth cohorts protects against paralytic polio caused by poliovirus type 2.

    更新日期:2019-12-25
  • Tuberculosis test results using fresh versus biobanked urine samples with FujiLAM
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Tobias Broger; Monde Muyoyeta; Andrew D Kerkhoff; Claudia M Denkinger; Emmanuel Moreau

    We agree with John T Connelly and colleagues that assessment of analyte stability and matrix effects must be part of every assay validation. It is, however, essential that validation is done with the assay under consideration, as different lipoarabinomannan (LAM) assays use different reagents that bind to different LAM epitopes with different stabilities or availabilities. Therefore, results from the research assay described by Connelly and colleagues, showing rapid signal loss, are not generalisable to other LAM tests. For the Fujifilm SILVAMP TB LAM (FujiLAM) assay (Fujifilm, Tokyo, Japan) described in our study, analyte stability and preanalytical and matrix effects were assessed by Fujifilm and met regulatory requirements for CE marking Declaration of Conformity in 2018. Here, we present additional and manufacturer-independent data.

    更新日期:2019-12-25
  • Measles outbreaks at mass gathering mostly occur at youth events
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Van Thuan Hoang; Philippe Gautret

    Despite some concerns regarding the risk of a measles outbreak at the 2019 Hajj, not a single case was identified by the Saudi Ministry of Health surveillance system, as noted by Saber Yezli and colleagues. Although measles is potentially highly transmissible in crowded settings, few documented outbreaks have been reported in the context of mass-gathering events.

    更新日期:2019-12-25
  • Adaptive trials of new antimicrobials for infections with carbapenem-resistant, Gram-negative bacteria
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Milo Gatti; Maddalena Giannella; Luigia Scudeller; Pierluigi Viale

    We agree with, and would like to further elaborate on, Simone Lanini and colleagues' proposal to use adaptive randomised controlled trials to improve research on infections with carbapenem-resistant Gram-negative bacteria. The efficacy of ceftazidime–avibactam for infections with carbapenem-resistant Gram-negative bacteria has only been assessed in observational studies,,  leaving several important real-world questions unanswered. First, is it preferable to use ceftazidime–avibactam in monotherapy or in combination therapy, and in case of the latter, what is the most effective combination therapy? Second, should ceftazidime–avibactam be administered in continuous or intermittent infusion? Finally, do specific populations require targeted dosing schedules? To address these questions with adaptive randomised controlled trials, we propose three scenarios in which clinical questions are explored through different adaptive designs ().

    更新日期:2019-12-25
  • 8-year M type surveillance of Streptococcus pyogenes in China
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Yuanhai You; Xiaomin Peng; Peng Yang; Quanyi Wang; Jianzhong Zhang
    更新日期:2019-12-25
  • 1 year after acute Zika virus infection in men
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Louis Bujan; Jean-Michel Mansuy; Safouane Hamdi; Christophe Pasquier; Guillaume Joguet

    Sexual transmission of Zika virus and the congenital abnormalities linked to infection of pregnant women have substantially modified many paradigms of arbovirology.

    更新日期:2019-12-25
  • Multigenic architecture of piperaquine resistance trait in Plasmodium falciparum
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Miguel Silva; Carla Calçada; Miguel Teixeira; Maria Isabel Veiga; Pedro Eduardo Ferreira

    William L Hamilton and colleagues and Rob W van der Pluijm and colleagues described the genomic evolution of Plasmodium falciparum malaria and the spread of resistance in this species to dihydroartemisinin–piperaquine in southeast Asia. Resistance in the region has been associated with crt polymorphisms,,  ,  copy number variations in plasmepsins,,  ,  ,  ,  and mdr1 genes.,  Despite compelling evidence regarding the determinant effect of crt polymorphisms on piperaquine resistance, the roles of plasmepsin variation and mdr1 genes, which were first identified in a 2017 phenotype–genotype association study, remain unclear. Therefore, we generated P falciparum Dd2 parasite lines with copy number variations in plasmepsin 2 or a hybrid of the plasmepsin 1 and plasmepsin 3 genes (plasmepsin 3–1) on a southeast-Asian genetic background to study the contribution of plasmepsins to piperaquine resistance ().

    更新日期:2019-12-25
  • Naegleria fowleri in Pakistan
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Mahwish Ali; Syed Babar Jamal; Syeda Mehpara Farhat

    Naegleria fowleri is responsible for the disease called primary amoebic meningoencephalitis (PAM). The infection is fatal in 98% of cases. The amoeba lives in warm, fresh water and enters the human brain through the nose, possibly during water activity or ablution for religious purposes. This amoeba is an emerging problem in Karachi, which is a major metropolitan city and coastal site of Pakistan. The first case of PAM was reported in 2008, and up until October, 2019, 146 cases had been reported from Karachi. In only a decade, the number of PAM cases in Pakistan exceeded those reported in the USA in half a century (ie, 142 cases between 1968 and 2019). The highest number of PAM cases in the USA were reported in children younger than 14 years, but in Pakistan, most cases are reported in adults aged 26–45 years, which points to the possibility of a genetically unique strain in Pakistan.

    更新日期:2019-12-25
  • Correction to Lancet Infect Dis 2019; published online Oct 30. https://doi.org/10.1016/S1473-3099(19)30540-7
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-11-06

    Campbell JR, Menzies D. What makes a score a winner? Lancet Infect Dis 2019; published online Oct 30. https://doi.org/10.1016/S1473-3099(19)30540-7—In this Comment, Matthew Saunders' name has been corrected and the references renumbered. These corrections have been made as of Nov 6, 2019, and will be made to the printed version.

    更新日期:2019-12-25
  • Correction to Lancet Infect Dis 2019; published online Nov 18. https://doi.org/10.1016/S1473-3099(19)30552-3
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-11-28

    Singer AC, Kirchhelle C, Roberts AP. (Inter)nationalising the antibiotic research and development pipeline. Lancet Infect Dis 2019; published online Nov 18. https://doi.org/10.1016/S1473-3099(19)30552-3—In this Personal View, a reference to the Global Antibiotic Research and Development Partnership as a push incentive on the first page has been removed, and two personal communications from Kevin Outterson have been reworded. The third sentence of the second paragraph should read “Developers can then move promising compounds to the US Biomedical Advanced Research and Development Authority (BARDA) for evaluation of possible funding of phase 2 and 3 trials”, and the third sentence of the third paragraph should read “In the case of the EU European Gram-Negative Antibacterial Engine initiative, €100 million of public funds during 6 years was apparently unable to generate sufficient private involvement by industry partners, leading to the initiative being scheduled to end in 2020”. These corrections have been made to the online version as of Nov 28, 2019, and will be made to the printed version.

    更新日期:2019-12-25
  • Correction to Lancet Infect Dis 2019; 19: 988–1000
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-12-03

    Dagnew AF, Ilhan A, Lee W-S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised clinical trials and post-hoc efficacy analysis. Lancet Infect Dis 2019; 19: 988–1000—In this Article, in page 997, the final paragraph of the results section should have stated “…excluding non-Hodgkin B-cell lymphoma and chronic lymphocytic leukaemia stratum (two [1·4%] of 148 vaccine group participants and one [0·8%] of 130 placebo group participants; per-protocol cohort for humoral immunogenicity, month 2).” This correction has been made to the online version as of Dec 3, 2019.

    更新日期:2019-12-25
  • Nigeria's widening tuberculosis gap
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Paul Adepoju
    更新日期:2019-12-25
  • Highlights from ASTMH 2019
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Marco De Ambrogi
    更新日期:2019-12-25
  • The pitfalls of sanitation work
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Talha Burki
    更新日期:2019-12-25
  • Infectious disease surveillance update
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Ruth Zwizwai

    As of Dec 4, the Samoan Ministry of Health has reported 4052 cases of since the outbreak began in September. 60 measles-related deaths have been reported whilst 177 measles cases were hospitalised as of Dec 4, including critically ill patients such as children in intensive care unit (n=20) as well as pregnant women (two) and neonatal cases (two). 1246 cases have been hospitalised so far during this outbreak. In response to the outbreak, door-to-door mass vaccination was undertaken on Dec 5–6, across the country.

    更新日期:2019-12-25
  • Research brief
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Dara Mohammadi

    Like bombs scudding across the water surface to hit a battleship, malaria-vector mosquitoes bounce across the top of as they probe for entry. With this knowledge — and with insecticide resistance compromising the effectiveness of insecticide-treated bednets—UK scientists have created the “Barrier Bednet” design. The simple design dangles a sheet of insecticide-treated netting vertically, like a tennis net, above the existing bednet. Because it's out of reach of people, the top netting can be treated with stronger insecticides than the rest of the bednet. They showed the design to be effective against wild Anopheles gambiae mosquitoes in field tests in Burkina Faso.

    更新日期:2019-12-25
  • You will learn anyway
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-11-29
    Jack Williamson
    更新日期:2019-12-25
  • The HIV epidemic in China: the story of a silent plague
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-11-29
    Quintina Dawson
    更新日期:2019-12-25
  • Stories of the 1918 influenza pandemic and its legacy
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-12-09
    Marta Gritti
    更新日期:2019-12-25
  • Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-30
    Christopher E Troeger; Ibrahim A. Khalil; Brigette F. Blacker; Molly H. Biehl; Samuel B. Albertson; Stephanie R M Zimsen; Puja C Rao; Degu Abate; Alireza Ahmadi; Mohamed Lemine Cheikh brahim Ahmed; Chalachew Genet Akal; Fares Alahdab; Noore Alam; Kefyalew Addis Alene; Vahid Alipour; Syed Mohamed Aljunid; Rajaa M Al-Raddadi; Nelson Alvis-Guzman; Saeed Amini; Nahla Hamed Anber; Mina Anjomshoa; Carl Abelardo T. Antonio; Jalal Arabloo; Olatunde Aremu; Hagos Tasew Atalay; Suleman Atique; Euripide F G A Avokpaho; Samah Awad; Ashish Awasthi; Alaa Badawi; Kalpana Balakrishnan; Joseph Adel Mattar Banoub; Aleksandra Barac; Quique Bassat; Neeraj Bedi; Derrick A. Bennett; Krittika Bhattacharyya; Zulfiqar A Bhutta; Ali Bijani; Josip Car; Félix Carvalho; Carlos A Castañeda-Orjuela; Devasahayam J Christopher; Lalit Dandona; Rakhi Dandona; Ahmad Daryani; Feleke Mekonnen Demeke; Aniruddha Deshpande; Shirin Djalalinia; Manisha Dubey; Eleonora Dubljanin; Eyasu Ejeta Duken; Maysaa El Sayed Zaki; Aman Yesuf Endries; Eduarda Fernandes; Florian Fischer; Nancy Fullman; William M. Gardner; Birhanu Geta; Keyghobad Ghadiri; Giuseppe Gorini; Alessandra C Goulart; Yuming Guo; Gessessew Bugssa Hailu; Arvin Haj-Mirzaian; Arya Haj-Mirzaian; Samer Hamidi; Hamid Yimam Hassen; Chi Linh Hoang; Mihaela Hostiuc; Zakir Hussain; Seyed Sina Naghibi Irvani; Spencer L. James; Ravi Prakash Jha; Jost B. Jonas; André Karch; Amir Kasaeian; Tesfaye Dessale Kassa; Nicholas J Kassebaum; Adane Teshome Kefale; Yousef Saleh Khader; Ejaz Ahmad Khan; Md Nuruzzaman Khan; Young-Ho Khang; Abdullah T Khoja; Ruth W Kimokoti; Adnan Kisa; Sezer Kisa; Niranjan Kissoon; Sonali Kochhar; Soewarta Kosen; Ai Koyanagi; Barthelemy Kuate Defo; G Anil Kumar; Dharmesh Kumar Lal; Cheru Tesema Leshargie; Shanshan Li; Rakesh Lodha; Erlyn Rachelle King Macarayan; Marek Majdan; Abdullah A. Mamun; Helena Manguerra; Addisu Melese; Ziad A Memish; Desalegn Tadese Mengistu; Tuomo J Meretoja; Tomislav Mestrovic; Bartosz Miazgowski; Erkin M Mirrakhimov; Babak Moazen; Karzan Abdulmuhsin Mohammad; Shafiu Mohammed; Lorenzo Monasta; Catrin E Moore; Jonathan F. Mosser; Seyyed Meysam Mousavi; Srinivas Murthy; Ghulam Mustafa; Javad Nazari; Cuong Tat Nguyen; Long Hoang Nguyen; Muhammad Imran Nisar; Molly R Nixon; Felix Akpojene Ogbo; Anselm Okoro; Andrew T Olagunju; Tinuke O Olagunju; Mahesh P A; Smita Pakhale; Maarten J Postma; Mostafa Qorbani; Reginald Quansah; Alireza Rafiei; Fakher Rahim; Vafa Rahimi-Movaghar; Rajesh Kumar Rai; Mohammad Sadegh Rezai; Aziz Rezapour; Maria Jesus Rios-Blancas; Luca Ronfani; Katherine Rosettie; Dietrich Rothenbacher; Saeed Safari; Zikria Saleem; Evanson Zondani Sambala; Abdallah M. Samy; Milena M Santric Milicevic; Benn Sartorius; Monika Sawhney; Seyedmojtaba Seyedmousavi; Masood Ali Shaikh; Aziz Sheikh; Mika Shigematsu; David L Smith; Joan B Soriano; Chandrashekhar T Sreeramareddy; Jeffrey D Stanaway; Mu'awiyyah Babale Sufiyan; Teklay G E Teklu; Mohamad-Hani Temsah; Belay Tessema; Bach Xuan Tran; Khanh Bao Tran; Irfan Ullah; Rachel L Updike; Tommi Juhani Vasankari; Yousef Veisani; Fiseha Wadilo Wada; Yasir Waheed; Marcia Weaver; Kirsten E Wiens; Charles Shey Wiysonge; Ebrahim M Yimer; Naohiro Yonemoto; Zoubida Zaidi; Heather J Zar; Afshin Zarghi; Stephen S Lim; Theo Vos; Ali H Mokdad; Christopher J L Murray; Hmwe Hmwe Kyu; Simon I. Hay; Robert C Reiner
    更新日期:2019-12-25
  • Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-30
    Christopher E Troeger; Ibrahim A Khalil; Brigette F Blacker; Molly H Biehl; Samuel B Albertson; Stephanie R M Zimsen; Puja C Rao; Degu Abate; Amha Admasie; Alireza Ahmadi; Mohamed Lemine Cheikh Brahim Ahmed; Chalachew Genet Akal; Fares Alahdab; Noore Alam; Kefyalew Addis Alene; Vahid Alipour; Syed Mohamed Aljunid; Rajaa M Al-Raddadi; Nelson Alvis-Guzman; Saeed Amini; Mina Anjomshoa; Carl Abelardo T Antonio; Jalal Arabloo; Olatunde Aremu; Hagos Tasew Atalay; Suleman Atique; Euripide F G A Avokpaho; Samah Awad; Ashish Awasthi; Alaa Badawi; Kalpana Balakrishnan; Joseph Adel Mattar Banoub; Aleksandra Barac; Quique Bassat; Neeraj Bedi; Derrick A Bennett; Krittika Bhattacharyya; Zulfiqar A Bhutta; Ali Bijani; Corey B Bills; Josip Car; Félix Carvalho; Carlos A Castañeda-Orjuela; Kate Causey; Devasahayam J Christopher; Aaron J Cohen; Lalit Dandona; Rakhi Dandona; Ahmad Daryani; Feleke Mekonnen Demeke; Shirin Djalalinia; Manisha Dubey; Eleonora Dubljanin; Eyasu Ejeta Duken; Maysaa El Sayed Zaki; Aman Yesuf Endries; Eduarda Fernandes; Florian Fischer; Joseph Frostad; Nancy Fullman; William M Gardner; Birhanu Geta; Keyghobad Ghadiri; Giuseppe Gorini; Alessandra C Goulart; Yuming Guo; Gessessew Bugssa Hailu; Arvin Haj-Mirzaian; Arya Haj-Mirzaian; Samer Hamidi; Hamid Yimam Hassen; Chi Linh Hoang; Nobuyuki Horita; Mihaela Hostiuc; Zakir Hussain; Seyed Sina Naghibi Irvani; Spencer L James; Ravi Prakash Jha; Jost B Jonas; André Karch; Amir Kasaeian; Tesfaye Dessale Kassa; Nicholas J Kassebaum; Adane Teshome Kefale; Yousef Saleh Khader; Ejaz Ahmad Khan; Gulfaraz Khan; Md Nuruzzaman Khan; Young-Ho Khang; Abdullah T Khoja; Ruth W Kimokoti; Adnan Kisa; Sezer Kisa; Niranjan Kissoon; Luke D Knibbs; Sonali Kochhar; Soewarta Kosen; Parvaiz A Koul; Ai Koyanagi; Barthelemy Kuate Defo; G Anil Kumar; Dharmesh Kumar Lal; Cheru Tesema Leshargie; Sonia Lewycka; Shanshan Li; Rakesh Lodha; Erlyn Rachelle King Macarayan; Marek Majdan; Abdullah A Mamun; Helena Manguerra; Varshil Mehta; Addisu Melese; Ziad A Memish; Desalegn Tadese Mengistu; Tuomo J Meretoja; Tomislav Mestrovic; Bartosz Miazgowski; Erkin M Mirrakhimov; Babak Moazen; Karzan Abdulmuhsin Mohammad; Shafiu Mohammed; Lorenzo Monasta; Catrin E Moore; Lidia Morawska; Jonathan F Mosser; Seyyed Meysam Mousavi; Srinivas Murthy; Ghulam Mustafa; Javad Nazari; Cuong Tat Nguyen; Huong Lan Thi Nguyen; Long Hoang Nguyen; Son Hoang Nguyen; Katie R Nielsen; Muhammad Imran Nisar; Molly R Nixon; Felix Akpojene Ogbo; Anselm Okoro; Andrew T Olagunju; Tinuke O Olagunju; Eyal Oren; Justin R Ortiz; Mahesh P A; Smita Pakhale; Maarten J Postma; Mostafa Qorbani; Reginald Quansah; Alireza Rafiei; Fakher Rahim; Vafa Rahimi-Movaghar; Rajesh Kumar Rai; Marissa Bettay Reitsma; Mohammad Sadegh Rezai; Aziz Rezapour; Maria Jesus Rios-Blancas; Luca Ronfani; Dietrich Rothenbacher; Salvatore Rubino; Zikria Saleem; Evanson Zondani Sambala; Abdallah M Samy; Milena M Santric Milicevic; Rodrigo Sarmiento-Suárez; Benn Sartorius; Miloje Savic; Monika Sawhney; Sonia Saxena; Alyssa Sbarra; Seyedmojtaba Seyedmousavi; Masood Ali Shaikh; Aziz Sheikh; Mika Shigematsu; David L Smith; Chandrashekhar T Sreeramareddy; Jeffrey D Stanaway; Mu'awiyyah Babale Sufiyan; Mohamad-Hani Temsah; Belay Tessema; Bach Xuan Tran; Khanh Bao Tran; Afewerki Gebremeskel Tsadik; Irfan Ullah; Rachel L Updike; Tommi Juhani Vasankari; Yousef Veisani; Fiseha Wadilo Wada; Yasir Waheed; Katie Welgan; Kirsten E Wiens; Charles Shey Wiysonge; Ebrahim M Yimer; Naohiro Yonemoto; Zoubida Zaidi; Heather J Zar; Stephen S Lim; Theo Vos; Ali H Mokdad; Christopher J L Murray; Hmwe Hmwe Kyu; Simon I Hay; Robert C Reiner
    更新日期:2019-12-25
  • Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-17
    David I Bernstein; Jeffrey Guptill; Abdollah Naficy; Raffael Nachbagauer; Francesco Berlanda-Scorza; Jodi Feser; Patrick C Wilson; Alicia Solórzano; Marie Van der Wielen; Emmanuel B Walter; Randy A Albrecht; Kristen N Buschle; Yao-qing Chen; Carine Claeys; Michelle Dickey; Haley L Dugan; Megan E Ermler; Debra Freeman; Min Gao; Christopher Gast; Jenna J Guthmiller; Rong Hai; Carole Henry; Linda Yu-Ling Lan; Monica McNeal; Anna-Karin E Palm; Dustin G Shaw; Christopher T Stamper; Weina Sun; Victoria Sutton; Micah E Tepora; Rahnuma Wahid; Heather Wenzel; Teddy John Wohlbold; Bruce L Innis; Adolfo García-Sastre; Peter Palese; Florian Krammer
    更新日期:2019-12-25
  • Serological response to three alternative series of hepatitis B revaccination (Fendrix, Twinrix, and HBVaxPro-40) in healthy non-responders: a multicentre, open-label, randomised, controlled, superiority trial
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-16
    Stijn F H Raven; Christian J P A Hoebe; Ann C T M Vossen; Leo G Visser; Jeannine L A Hautvast; Anna H E Roukens; Jim E van Steenbergen
    更新日期:2019-12-25
  • Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-29
    Sébastien DS Pion; Hugues Nana-Djeunga; Yannick Niamsi-Emalio; Cédric B Chesnais; Hugo Deléglise; Charles Mackenzie; Wilma Stolk; Daniel A Fletcher; Amy D Klion; Thomas B Nutman; Michel Boussinesq; Joseph Kamgno
    更新日期:2019-12-25
  • A household-level score to predict the risk of tuberculosis among contacts of patients with tuberculosis: a derivation and external validation prospective cohort study
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-30
    Matthew J Saunders; Tom Wingfield; Sumona Datta; Rosario Montoya; Eric Ramos; Matthew R Baldwin; Marco A Tovar; Benjamin E W Evans; Robert H Gilman; Carlton A Evans
    更新日期:2019-12-25
  • Long-term survival and cause-specific mortality of patients newly diagnosed with tuberculosis in São Paulo state, Brazil, 2010–15: a population-based, longitudinal study
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-29
    Otavio T Ranzani; Laura C Rodrigues; Sidney Bombarda; Cátia M Minto; Eliseu A Waldman; Carlos R R Carvalho
    更新日期:2019-12-25
  • Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-10-21
    Gill Schierhout; Skye McGregor; Antoine Gessain; Lloyd Einsiedel; Marianne Martinello; John Kaldor
    更新日期:2019-12-25
  • Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Lesley Uttley; Christopher Carroll; Ruth Wong; David A Hilton; Matt Stevenson
    更新日期:2019-12-25
  • The public health crisis of underimmunisation: a global plan of action
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-11-06
    Lawrence O Gostin; James G Hodge; Barry R Bloom; Ayman El-Mohandes; Jonathan Fielding; Peter Hotez; Ann Kurth; Heidi J Larson; Walter A Orenstein; Kenneth Rabin; Scott C Ratzan; Daniel Salmon

    Vaccination is one of public health's greatest achievements, responsible for saving billions of lives. Yet, 20% of children worldwide are not fully protected, leading to 1·5 million child deaths annually from vaccine-preventable diseases. Millions more people have severe disabling illnesses, cancers, and disabilities stemming from underimmunisation. Reasons for falling vaccination rates globally include low public trust in vaccines, constraints on affordability or access, and insufficient governmental vaccine investments. Consequently, an emerging crisis in vaccine hesitancy ranges from hyperlocal to national and worldwide. Outbreaks often originate in small, insular communities with low immunisation rates. Local outbreaks can spread rapidly, however, transcending borders. Following an assessment of underlying determinants of low vaccination rates, we offer an action based on scientific evidence, ethics, and human rights that spans multiple governments, organisations, disciplines, and sectors.

    更新日期:2019-12-25
  • WHO international standard for anti-rubella: learning from its application
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-09-06
    Sarah L Kempster; Neil Almond; Wayne Dimech; Liliane Grangeot-Keros; Daniela Huzly; Joseph Icenogle; Haja Sittana El Mubarak; Mick N Mulders; C Micha Nübling

    The WHO international standard for anti-rubella was first established in the 1960s when clinical diagnostics were in their infancy. Since the endorsement of the first international standard for anti-rubella IgG (RUBI-1-94), new rubella vaccines have been developed and global coverage of rubella vaccination has increased. Methods used to measure concentrations of anti-rubella IgG have also evolved to rapid, high-throughput binding assays, which have replaced often cumbersome and highly technical functional assays. During this timeframe, the protective concentration of antibody was set at 10 IU/mL by extrapolation of functional assay correlates; however, the subpopulation of antibodies within a polyclonal serum that confer protection remained undefined. Anti-rubella assays have variable formats, including antigens used, such that the same clinical sample tested on different assays can report different values with potentially devastating consequences, such as recommending to terminate pregnancy. WHO convened a meeting of experts in the rubella field to discuss the use of RUBI-1-94 and the potential future role of this international standard. The main conclusions of this meeting questioned the appropriateness of 10 IU/mL as the cutoff for protection and acknowledged the continuing role of RUBI-1-94 as a reference preparation to address analytical sensitivity and assay variation.

    更新日期:2019-12-25
  • PCR correction strategies for malaria drug trials: updates and clarifications
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-09-17
    Ingrid Felger; Georges Snounou; Ian Hastings; Joerg J Moehrle; Hans-Peter Beck
    更新日期:2019-12-25
  • Brucellosis mimicking herpes simplex virus encephalitis
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2020-01-01
    Ashok K Pannu; Atul Saroch; Navneet Sharma; Vikas Bhatia
    更新日期:2019-12-25
  • Balancing sensitivity and specificity of Zika virus case definitions
    Lancet Infect. Dis. (IF 27.516) Pub Date : 2019-12-20
    Gabriela Paz-Bailey; Christopher J Gregory

    In a study published in The Lancet Infectious Diseases, Raquel Burger-Calderon and colleagues characterise the clinical profile of Zika virus infection and assess the performance of WHO and Pan American Health Organization case definitions in a large paediatric cohort from Nicaragua. They show that Zika disease primarily manifests with undifferentiated fever or afebrile rash, and that the occurrence of symptoms increases with age. As a result, Zika in children is likely to be missed by recommended case definitions more frequently than in adults. Sensitivity improved with age, as older cases presented with more symptoms, but at most, only half of the symptomatic cases were captured. The most commonly presenting symptom was rash; other symptoms, such as arthralgia and periarticular oedema, were equally rare in cases with and without Zika. The study testing algorithm helped identify that previous dengue infection did not change the clinical presentation of Zika. Cases only identified by serology were milder than were PCR positive cases, suggesting that studies that only used PCR positivity to confirm cases might be more aligned with recommended case definitions. In summary, these definitions missed most cases and mainly captured cases in older children with dengue-like illness. The authors call for case definitions to be revised to better capture the full clinical spectrum of Zika virus.

    更新日期:2019-12-21
Contents have been reproduced by permission of the publishers.
导出
全部期刊列表>>
2020新春特辑
限时免费阅读临床医学内容
ACS材料视界
科学报告最新纳米科学与技术研究
清华大学化学系段昊泓
自然科研论文编辑服务
中国科学院大学楚甲祥
中国科学院微生物研究所潘国辉
中国科学院化学研究所
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug